Friday, May 20, 2022 9:48:14 PM
Supreme Court Update:
1) Law 360 published an article on our Petition today. Check out the utter arrogance of Hikma's spokesman. Article is in the link below.
2) Hikma has waived their right to file a response to the Petition. I expect Reddys to do the same. Hikma's filing is in the link below.
https://drive.google.com/drive/folders/1b1-oyiWtg6DQK6YwXtXbELStC71-8PCx?usp=sharing
This waiver is a tactic and is not the type of gift that waivers are in most litigation. The Petition now goes out to the Cert. Pool for review by he Clerks, and then the Justices.
Hikma is playing the odds that it certiorari will be denied without them having to do any work. If, however, the Court decides that the Petition warrants further consideration, they will send a letter requesting a response in 30 days. While I initially thought Hikma was taking a big risk, all the literature says that the Court does not enter reversals without first hearing from the other side.
Thus the next big event will be either the Court denies the Petition, or asks our adversaries to submit opposition.
1) Law 360 published an article on our Petition today. Check out the utter arrogance of Hikma's spokesman. Article is in the link below.
2) Hikma has waived their right to file a response to the Petition. I expect Reddys to do the same. Hikma's filing is in the link below.
https://drive.google.com/drive/folders/1b1-oyiWtg6DQK6YwXtXbELStC71-8PCx?usp=sharing
This waiver is a tactic and is not the type of gift that waivers are in most litigation. The Petition now goes out to the Cert. Pool for review by he Clerks, and then the Justices.
Hikma is playing the odds that it certiorari will be denied without them having to do any work. If, however, the Court decides that the Petition warrants further consideration, they will send a letter requesting a response in 30 days. While I initially thought Hikma was taking a big risk, all the literature says that the Court does not enter reversals without first hearing from the other side.
Thus the next big event will be either the Court denies the Petition, or asks our adversaries to submit opposition.
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
